^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

CCND1 overexpression

i
Other names: CCND1, BCL1, D11S287E, PRAD1, U21B31, Cyclin D1
Entrez ID:
Related biomarkers:
5d
New P2 trial
|
CCND1 (Cyclin D1)
|
Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
|
Rituxan (rituximab) • Brukinsa (zanubrutinib)
7d
New P1/2 trial
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • CD19 (CD19 Molecule) • BCL6 (B-cell CLL/lymphoma 6) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • IL10 (Interleukin 10)
|
Chr t(11;14) • CD19 positive • CCND1 overexpression • BCL6 rearrangement • Chr t(11;14)(q13;q32) • BCL2 rearrangement • CD20 negative
|
cyclophosphamide • fludarabine IV • autologous TRAC locus-inserted CD19-STAR-T
15d
Enrollment open
|
TP53 (Tumor protein P53) • CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • KMT2D (Lysine Methyltransferase 2D) • NOTCH2 (Notch 2) • BIRC3 (Baculoviral IAP repeat containing 3) • FAT1 (FAT atypical cadherin 1) • POT1 (Protection of telomeres 1) • NSD2 (Nuclear Receptor Binding SET Domain Protein 2) • UBR5 (Ubiquitin Protein Ligase E3 Component N-Recognin 5)
|
CD20 positive • Chr t(11;14) • KMT2D mutation • BIRC3 mutation • CCND1 overexpression • SMARCA4 mutation • Chr t(11;14)(q13;q32) • MYC positive
|
Rituxan (rituximab) • cyclophosphamide • Calquence (acalabrutinib) • Tecartus (brexucabtagene autoleucel) • fludarabine IV
21d
Whole Transcriptome Sequencing Reveals Cancer-Related, Prognostically Significant Transcripts and Tumor-Infiltrating Immunocytes in Mantle Cell Lymphoma. (PubMed, Cells)
Similarly, high expression of MSTRG.153013.3, an overexpressed alternative transcript, was associated with shortened MCL survival...WTS results were cross-validated with qRT-PCR of selected transcripts as well as linear correlation analyses. In conclusion, expression levels of oncogenesis-associated transcripts and/or the ratios of microenvironmental immunocytes in MCL tumors may be used to improve prognostication, thereby leading to better patient management and outcomes.
Journal
|
CD8 (cluster of differentiation 8) • CCND1 (Cyclin D1) • ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1) • SOX11 (SRY-Box Transcription Factor 11) • VCAM1 (Vascular Cell Adhesion Molecule 1) • PCA3 (Prostate cancer associated 3)
|
CCND1 overexpression • CD8 expression • SOX11 expression
|
R1530
1m
Whole-Genome Analysis of Histone Modifications Reveals New Insights into the Biology and Clinical Behavior of Mantle Cell Lymphoma Subtypes (ASH 2022)
The results obtained with this multilayer chromatin analysis confirm that MCL is a heterogeneous disease showing widespread differences between the 2 subtypes. cMCL present a clear de novo chromatin activation associated with upregulation of key genes involved in cMCL pathogenesis, while nnMCL cases seem to be characterized by the absence of this signature and an overall chromatin profile more similar to normal B cells. Moreover, the level of activation in regulatory regions in cMCL seems to be related with the clinical outcome of the patients, with more activation associated with shorter overall survival.
Clinical • Epigenetic controller
|
CCND1 (Cyclin D1)
|
CCND1 overexpression
1m
A Phase1/1b Dose Escalation/Dose Expansion Study of Prgn-3007 Ultracar-T Cells in Patients with Advanced Hematologic and Solid Tumor Malignancies (ASH 2022)
Study subjects undergo leukapheresis followed by lymphodepletion with either fludarabine 30mg/m2 and cyclophosphamide 500mg/m2 for 3 days (Arm 1) or 60 mg/kg cyclophosphamide for 2 days (Arm 2). All subjects will be followed for adverse events, CAR-T-related toxicities, disease response and PRGN-3007 cell expansion and persistence. In addition, the mechanisms of safety and effectiveness of PRGN-3007 cells will be evaluated with correlative assays of specific immune response pathways.
Clinical • P1 data • CAR T-Cell Therapy • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CCND1 (Cyclin D1) • ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1) • IL15 (Interleukin 15)
|
PD-1 expression • CCND1 overexpression • ROR1 expression
|
cyclophosphamide • fludarabine IV • Ovarian cancer CAR-T therapy • PRGN-3005 • PRGN-3007
1m
Constitutive PRMT5 Expression Drives Spontaneous Lymphoblastic Lymphoma In Vivo (ASH 2022)
Tg813 engrafted animals treated with C220 (10mg/kg) showed improved survival compared to vehicle-treated mice (p<0.001). This preclinical model supports the hypothesis that PRMT5 over-expression provides cancer driver activity and a unique opportunity to study the role of this oncogene in an immune-competent, in vivo model system.
Preclinical • PD(L)-1 Biomarker • IO biomarker
|
CCND1 (Cyclin D1) • PD-1 (Programmed cell death 1) • CD4 (CD4 Molecule) • PRMT5 (Protein Arginine Methyltransferase 5) • CD99 (CD99 Molecule) • RELA (RELA Proto-Oncogene) • E2F1 (E2F transcription factor 1)
|
PD-1 expression • CCND1 overexpression • CD4 expression • PRMT5 overexpression
1m
Integrative Analysis of Genetic and Tumor Microenvironment Topology to Delineate Prognostic Subtypes in Mantle Cell Lymphoma (ASH 2022)
Thus, this study suggests a new angle of ATM mutations in MCL pathogenesis which could improve risk stratification. Overall, this study may unravel distinct mechanisms of tumorigenesis with relevant clinical and biological implications.
TP53 (Tumor protein P53) • ATM (ATM serine/threonine kinase) • CD8 (cluster of differentiation 8) • CCND1 (Cyclin D1) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CD4 (CD4 Molecule) • NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1)
|
TP53 mutation • ATM mutation • CCND1 overexpression • ATM expression • ATM positive • TP53 mutation + ATM mutation
1m
CARAMEL: Acalabrutinib and Rituximab in Previously Untreated Mantle Cell Lymphoma (clinicaltrials.gov)
P2, N=26, Not yet recruiting, University College, London | Trial completion date: Aug 2023 --> May 2026 | Trial primary completion date: Aug 2023 --> May 2026
Trial completion date • Trial primary completion date
|
CCND1 (Cyclin D1)
|
Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
|
Rituxan (rituximab) • Calquence (acalabrutinib)
2ms
EVI1 exerts distinct roles in AML via ERG and cyclin D1 promoting a chemoresistance and immune-suppressive environment. (PubMed, Blood Adv)
Overexpression of EVI1 and cyclin D1 was associated with interferon-γ signature and increased expression of chemokines, with increased exhaustion molecules in T cells also in human AML datasets. These data collectively suggest that ERG and cyclin D1 play pivotal roles in the biology of EVI1+ AML, where ERG forms aggressive disease nature and chemoresistance, and cyclin D1 leads to interferon-γ signature and exhausted T cell phenotypes, which could be potentially targeted.
Journal
|
CCND1 (Cyclin D1) • IFNG (Interferon, gamma) • KMT2A (Lysine Methyltransferase 2A) • ERG (ETS Transcription Factor ERG) • CDK6 (Cyclin-dependent kinase 6) • MECOM (MDS1 And EVI1 Complex Locus)
|
CCND1 overexpression
2ms
Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov)
P2, N=15, Active, not recruiting, City of Hope Medical Center | Suspended --> Active, not recruiting | N=30 --> 15
Enrollment closed • Enrollment change
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • FCER2 (Fc Fragment Of IgE Receptor II)
|
Chr t(11;14) • CCND1 overexpression
|
Copiktra (duvelisib) • ETP-47187
2ms
Trial suspension
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • FCER2 (Fc Fragment Of IgE Receptor II)
|
Chr t(11;14) • CCND1 overexpression
|
Copiktra (duvelisib) • ETP-47187
2ms
Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma (clinicaltrials.gov)
P2, N=27, Suspended, City of Hope Medical Center | Trial completion date: Mar 2023 --> Sep 2023 | Trial primary completion date: Sep 2022 --> Sep 2023
Trial completion date • Trial primary completion date • Combination therapy
|
CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1)
|
Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
|
Calquence (acalabrutinib) • Ukoniq (umbralisib) • Utuxin (ublituximab)
2ms
Allogenic CD19-targeting CAR-γδT Cell Therapy in r/r NHL (clinicaltrials.gov)
P1/2, N=30, Recruiting, Chinese PLA General Hospital
New P1/2 trial
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • CD19 (CD19 Molecule) • BCL6 (B-cell CLL/lymphoma 6) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • IL10 (Interleukin 10)
|
Chr t(11;14) • CD19 positive • CCND1 overexpression • BCL6 rearrangement • Chr t(11;14)(q13;q32) • BCL2 rearrangement • CD20 negative
|
cyclophosphamide • fludarabine IV
3ms
Enrollment closed • Combination therapy • Pan tumor
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6)
|
Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • BCL2 rearrangement
|
parsaclisib (INCB50465) • Monjuvi (tafasitamab-cxix)
3ms
A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL (clinicaltrials.gov)
P2, N=50, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Aug 2023 --> Aug 2024 | Trial primary completion date: Aug 2022 --> Aug 2023
Trial completion date • Trial primary completion date
|
PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • CCND1 (Cyclin D1) • CD19 (CD19 Molecule) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • PIK3CD (Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
|
Chr t(11;14) • CCND1 overexpression
|
Zydelig (idelalisib) • Arzerra (ofatumumab)
3ms
Enrollment open • Enrollment change • Combination therapy • Pan tumor
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6)
|
Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • BCL2 rearrangement
|
parsaclisib (INCB50465) • Monjuvi (tafasitamab-cxix)
3ms
Clinicopathologic Features and Treatment of CD10-Positive Mantle Cell Lymphoma: A Case Report and Review of Literature. (PubMed, Pathol Oncol Res)
It is often distinguished from B cell lymphomas of germinal center cell origin by the absence of CD10 expression. Here we report the unique clinicopathologic features of a patient with CD10 MCL with gastrointestinal involvement and review current literature identifying this unique immunophenotype.
Review
|
CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6) • CD5 (CD5 Molecule) • MME (Membrane Metalloendopeptidase) • SPN (Sialophorin) • FCER2 (Fc Fragment Of IgE Receptor II)
|
Chr t(11;14) • CCND1 overexpression
3ms
New P2 trial
|
TP53 (Tumor protein P53) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CDKN2A (Cyclin-dependent kinase inhibitor 2A) • CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • NOTCH2 (Notch 2) • NSD2 (Nuclear Receptor Binding SET Domain Protein 2)
|
TP53 mutation • Chr del(17p) • CD20 positive • Chr t(11;14) • CDKN2A mutation • CCND1 overexpression • Chr t(11;14)(q13;q32) • MYC positive • BCL2 amplification
|
Venclexta (venetoclax) • pirtobrutinib (LOXO-305)
3ms
IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • CD5 (CD5 Molecule)
|
CD20 positive • Chr t(11;14) • CCND1 overexpression
3ms
Diffuse Mesenteric Lymphadenopathy and Duodenal Polyposis Secondary to Mantle Cell Lymphoma: A Rare Case Report (ACG 2022)
Only a few case reports are available in the literature about primary gastrointestinal mantle cell lymphoma; thus, little is known about the outcome, the response to treatment, and the duration of remission in primary GI MCL patients. Figure: Figure 1: (A) EGD image shows diffuse polyposis in the proximal duodenum, (B) EGD image with narrow-band imaging shows diffuse duodenal polyposis, (C) Endoscopic ultrasound shows peripancreatic lymphadenopathy, (D) Endoscopic ultrasound with fine-needle biopsy of the thickened duodenal wall.
Clinical
|
CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • IGH (Immunoglobulin Heavy Locus) • CD5 (CD5 Molecule)
|
CCND1 overexpression
3ms
Enrollment closed • Enrollment change • Combination therapy • Pan tumor
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6)
|
Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • BCL2 rearrangement
|
parsaclisib (INCB50465) • Monjuvi (tafasitamab-cxix)
3ms
Tipping the balance: toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma. (PubMed, Leukemia)
Here, we describe the underlying mechanisms of venetoclax resistance in MCL, such as upregulation of BCL-X or MCL-1, and the recent (clinical) progress in the development of inhibitors for these BCL-2 family members, followed by the transcriptional and (post-)translational (dys)regulation of the BCL-2 family proteins, including the role of the lymphoid organ microenvironment. Based upon these insights, we discuss how rational combinations of venetoclax with other therapies can be exploited to prevent or overcome venetoclax resistance and improve MCL patient outcome.
Review • Journal • Combination therapy • IO biomarker
|
MCL1 (Myeloid cell leukemia 1) • CCND1 (Cyclin D1) • BCL2L1 (BCL2-like 1)
|
Chr t(11;14) • CCND1 overexpression
|
Venclexta (venetoclax)
3ms
Enrollment change
|
TP53 (Tumor protein P53) • CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • KMT2D (Lysine Methyltransferase 2D) • NOTCH2 (Notch 2) • BIRC3 (Baculoviral IAP repeat containing 3) • FAT1 (FAT atypical cadherin 1) • POT1 (Protection of telomeres 1) • NSD2 (Nuclear Receptor Binding SET Domain Protein 2) • UBR5 (Ubiquitin Protein Ligase E3 Component N-Recognin 5)
|
CD20 positive • Chr t(11;14) • KMT2D mutation • BIRC3 mutation • CCND1 overexpression • SMARCA4 mutation • Chr t(11;14)(q13;q32) • MYC positive
|
Rituxan (rituximab) • cyclophosphamide • Calquence (acalabrutinib) • Tecartus (brexucabtagene autoleucel) • fludarabine IV
3ms
Regulation of Cyclin D1 Degradation by Ubiquitin Specific Protease 27X is Critical for Cancer Cell Proliferation and Tumor Growth. (PubMed, Mol Cancer Res)
Implications: As a deubiquitinating enzyme, USP27X is a druggable target. Our study illuminates new avenues for therapeutic intervention in CCND1-driven cancers.
Journal
|
CCND1 (Cyclin D1)
|
CCND1 overexpression • CCND1 expression
3ms
Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma (clinicaltrials.gov)
P2, N=30, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Jun 2022 --> Jun 2023 | Trial primary completion date: Jun 2022 --> Jun 2023
Trial completion date • Trial primary completion date
|
CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1)
|
CD20 positive • Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
|
ibrutinib • Calquence (acalabrutinib)
4ms
Overexpressed Cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4/6 inhibitor in breast cancer that can be reversed by PI3K/mTOR inhibitors. (PubMed, Sci China Life Sci)
Targeting PI3K/mTOR pathway with a specific PI3Kα inhibitor (BYL719) or an mTOR inhibitor (everolimus) reduced the protein levels of Cyclin D1 and CDK4, and restored the sensitivity to palbociclib. The tumor samples expressed significantly higher levels of Cyclin D1, CDK4, p-AKT and p-4E-BP1 after progression on palbociclib treatment. In conclusion, our findings suggest that overexpressed Cyclin D1 and CDK4 proteins lead to the resistance to CDK4/6 inhibitor and PI3K/mTOR inhibitors are able to restore the sensitivity to CDK4/6 inhibitors, which provides the biomarker and rationale for the combinational use of CDK4/6 inhibitors and PI3K/mTOR inhibitors after CDK4/6 inhibitor resistance in breast cancer.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • CCND1 (Cyclin D1) • CCNE1 (Cyclin E1) • CDK2 (Cyclin-dependent kinase 2) • EIF4EBP1 (Eukaryotic translation initiation factor 4E binding protein 1)
|
HER-2 negative • CCND1 overexpression • CCND1 expression
|
Ibrance (palbociclib) • everolimus • Piqray (alpelisib)
4ms
Multiple myeloma with t(11;14): unique biology and evolving landscape. (PubMed, Am J Cancer Res)
However, it is clear that t(11;14) multiple myeloma represents a distinct subset and a rare opportunity for targeted therapy with BCL-2 inhibition. In this review, we first describe the underlying biology of t(11;14) multiple myeloma cells, then summarize the body of literature evaluating the prognosis of patients with t(11;14) multiple myeloma, and finally discuss therapeutic implications.
Review • Journal • IO biomarker
|
CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1)
|
Chr t(11;14) • CCND1 overexpression
4ms
CCND1 amplification and cyclin D1 overexpression correlate with adverse outcome in vulvar squamous cell carcinoma (ECP 2022)
Our findings indicate that CCND1 is amplified and overexpressed in a significant proportion of VSCC, mostly in HPV-independent tumours. Cyclin D1 overexpression is strongly asso-ciated with adverse patient outcome (worse disease-specific and disease-free survival) and could be a useful tool for prognostic stratification. Innovative targeted therapies could be explored based on these findings.
Adverse events
|
CCND1 (Cyclin D1)
|
CCND1 amplification • CCND1 overexpression
4ms
Hidden mantle cell lymphoma (ECP 2022)
A prostatic adenocarcinoma can extremely rarely be in a coexistence with undiagnosed lymphoproliferative disease, such as non Hodgkin mantle cell lymphoma in our case. This lymphoma is usually synchronously present with plasma cell dyscrasia or granulomatous diseases such as sarcoidosis. It can also occur with metastasis from a diferent anatomical site, but in the same lymph node.
IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6) • CD5 (CD5 Molecule) • MME (Membrane Metalloendopeptidase)
|
BCL2 expression • CD20 expression • CCND1 overexpression • CD5 overexpression
4ms
Immunohistochemical Overexpression of Cyclin D1 in Tunisian Invasive Breast Carcinoma Women. (PubMed, Arch Iran Med)
These results confirm that cyclin D1 overexpression can be employed as a beneficial prognostic marker and suggest that anti-cyclin D1 therapy may be efficient, especially for ER positive tumors.
Retrospective data • Journal
|
ER (Estrogen receptor) • PGR (Progesterone receptor) • CCND1 (Cyclin D1)
|
ER positive • CCND1 overexpression
4ms
New P1 trial
|
TP53 (Tumor protein P53) • CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • KMT2D (Lysine Methyltransferase 2D) • NOTCH2 (Notch 2) • BIRC3 (Baculoviral IAP repeat containing 3) • FAT1 (FAT atypical cadherin 1) • POT1 (Protection of telomeres 1) • NSD2 (Nuclear Receptor Binding SET Domain Protein 2) • UBR5 (Ubiquitin Protein Ligase E3 Component N-Recognin 5)
|
CD20 positive • Chr t(11;14) • KMT2D mutation • BIRC3 mutation • CCND1 overexpression • SMARCA4 mutation • Chr t(11;14)(q13;q32) • MYC positive
|
Rituxan (rituximab) • cyclophosphamide • Calquence (acalabrutinib) • Tecartus (brexucabtagene autoleucel) • fludarabine IV
4ms
CLDN6 inhibits breast cancer cell malignant behavior by suppressing ERK signaling. (PubMed, Cell Signal)
In conclusion, CLDN6 suppressed ERK/Sp1/cyclin D1 and ERK/IL-8 signaling to inhibit proliferation, migration and invasion in breast cancer cells. The mechanism may provide experimental evidence for the treatment of breast cancer targeting CLDN6.
Journal
|
CCND1 (Cyclin D1) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CLDN6 (Claudin 6) • CXCR2 (Chemokine (C-X-C motif) receptor 2)
|
CCND1 overexpression • CCND1 expression • CLDN6 expression • CXCL8 expression • CXCL8 overexpression
4ms
Knockdown of circ_0004585 enhances the chemosensitivity of colorectal cancer cells to 5-fluorouracil via the miR-874-3p/CCND1 axis. (PubMed, Histol Histopathol)
Circ_0004585 promotes the development of CRC and increases 5-FU resistance in CRC through the miR-874-3p/CCND1 axis. These results suggest that circ_0004585 may be a therapeutic target for 5-FU-ressitant CRC.
Journal
|
CCND1 (Cyclin D1) • CASP3 (Caspase 3) • CASP9 (Caspase 9)
|
CCND1 overexpression • CCND1 expression
|
5-fluorouracil
5ms
BRUIN MCL-321, a Phase 3 Open-label, Randomized Study of Pirtobrutinib versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated, BTK Inhibitor Naïve Mantle Cell Lymphoma (Trial in Progress) (PPLC 2022)
BRUIN MCL-321 is a randomized, open-label, global phase 3 study comparing pirtobrutinib monotherapy versus investigator’s choice of covalent BTKi monotherapy (ibrutinib, acalabrutinib, or zanubrutinib) in patients with previously treated, BTKi naïve MCL. This study is a Trial in Progress. The conclusions will be presented at a later date. 1Mato et al.
Clinical • P3 data
|
CCND1 (Cyclin D1)
|
CCND1 overexpression • BTK C481
|
ibrutinib • Brukinsa (zanubrutinib) • Calquence (acalabrutinib) • pirtobrutinib (LOXO-305)
5ms
A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin Lymphoma (clinicaltrials.gov)
P1/2, N=50, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting | Initiation date: Feb 2022 --> Jul 2022
Enrollment open • Trial initiation date • Combination therapy
|
CCND1 (Cyclin D1)
|
Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
|
AZD0466
5ms
Let-7i-3p inhibits the cell cycle, proliferation, invasion, and migration of colorectal cancer cells via downregulating CCND1. (PubMed, Open Med (Wars))
However, exogenously expressing CCND1 alleviated these effects. Taken together, our findings may provide new insight into the pathogenesis of CRC and let-7i-3p/CCND1 might function as new therapeutic targets for CRC.
Journal
|
CCND1 (Cyclin D1)
|
CCND1 overexpression • CCND1 expression
5ms
Prognostic and Predictive Value of CCND1/Cyclin D1 Amplification in Breast Cancer With a Focus on Postmenopausal Patients: A Systematic Review and Meta-Analysis. (PubMed, Front Endocrinol (Lausanne))
With standardised methods and cut offs for the detection of CCND1 amplification, CCND1 amplification would have potential as a predictive biomarker in breast cancer patients. https://www.crd.york.ac.uk/prospero/, identifier CRD42020208179.
Retrospective data • Review
|
ER (Estrogen receptor) • CCND1 (Cyclin D1)
|
ER positive • CCND1 amplification • CCND1 overexpression
5ms
Mantle cell lymphoma negative for t(11,14) involving the kidneys: a case report. (PubMed, J Med Case Rep)
We present a case of a rare presentation of Mantle cell lymphoma while describing the clinical presentation and diagnostic and treatment approaches. This case report can assist physicians in the clinical work-up and treatment of patients with similar diagnosis or presentation.
Journal
|
CCND1 (Cyclin D1)
|
Chr t(11;14) • CCND1 overexpression
|
ibrutinib • Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • oxaliplatin • vincristine • prednisone • dexamethasone
5ms
Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma (clinicaltrials.gov)
P1, N=18, Completed, Kami Maddocks, MD | Active, not recruiting --> Completed
Trial completion
|
CCND1 (Cyclin D1)
|
CCND1 overexpression
|
Rituxan (rituximab) • buparlisib (AN2025)